At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IVA Inventiva S.A.
Closed Good Friday 04-17 16:00:00 EDT
3.36
+0.05
+1.51%
盘后3.31
-0.05-1.49%
16:00 EDT
| High3.44 | Low3.16 | Vol15.37K |
| Open3.43 | D1 Closing3.31 | Amplitude8.46% |
| Mkt Cap321.43M | Tradable Cap135.54M | Total Shares95.66M |
| T/O52.11K | T/O Rate0.04% | Tradable Shares40.34M |
| P/B-3.57 | ROE-1642.76% | EPS-3.19 |
| 52wk High3.90 | 52wk Low1.53 | P/E-1.05 |
| Dividend0.00 | Div.Yield0.00 | ROA-113.34% |
Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F
GlobeNewswire · 04-15 20:00
Inventiva Is Maintained at Buy by Guggenheim
Dow Jones · 04-04
Is Elicio Therapeutics, Inc. (ELTX) Stock Outpacing Its Medical Peers This Year?
Zacks · 04-04
Inventiva price target lowered to $9 from $12 at Guggenheim
TIPRANKS · 04-04
Inventiva Sa : Guggenheim Cuts Target Price to $9.00 From $12.00
THOMSON REUTERS · 04-04
Inventiva Price Target Maintained With a $13.00/Share by HC Wainwright & Co.
Dow Jones · 04-02
Inventiva achieves milestone with Phase 3 study enrollment, says H.C. Wainwright
TIPRANKS · 04-02
Inventiva Completes Enrollment in Phase 3 Study of Liver Treatment
MT Newswires Live · 04-01
Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis
GlobeNewswire · 04-01
Inventiva (IVA) Gets a Buy from Canaccord Genuity
TIPRANKS · 04-01
Inventiva SA (IVEVF) (Q4 2024) Earnings Call Highlights: Navigating Financial Challenges and ...
GuruFocus.com · 03-28
Inventiva FY24 EPS €(3.08) Down From €(2.43) YoY; Revenue €9.2 Million Down From €17.48 Million YoY
Benzinga · 03-26
Inventiva reports its 2024 full year results and provides a business update
GlobeNewswire · 03-26
Inventiva SA expected to post a loss of 52 cents a share - Earnings Preview
Reuters · 03-24
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones · 03-24
Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results
GlobeNewswire · 03-19
Optimistic Buy Rating for Inventiva Driven by Lanifibranor’s Promising Phase 3 Prospects and Safety Profile
TIPRANKS · 02-21
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Organon (OGN) and Inventiva (IVA)
TIPRANKS · 02-12
Inventiva Reports €9.2M 2024 Revenues, €96.6M Cash As Of December 31, 2024; €116M Tranche Of €348M Financing Secured; Last Patient Screened For NATiV3 Phase 3 Lanifibranor Trial; Workforce Cut By 50% To Focus On Lanifibranor Development
Benzinga · 02-10
Inventiva Price Target Maintained With a $13.00/Share by HC Wainwright & Co.
Dow Jones · 01-30
Introduction
Company Name.
Inventiva S.A.
Affiliated Markets:
NASDAQ
Listing Date:
2020-07-10
Main Business:
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.
Issue price:
14.40
Invest in Global Markets with Tiger Brokers!Open App